Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia – guidance (TA 451)

Ponatinib is recommended as an option for chronic, accelerated, or blast phase chronic myeloid leukaemia in adults, and Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults with set restrictions

For chronic myeloid leukaemia, ponatinib is restricted to use where:

 

• The disease is resistant to dasatinib or nilotinib or

• They cannot tolerate dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or

• The T315I gene mutation is present.

 

For acute lymphoblastic leukaemia, ponatinib is restricted to use where:

 

• The disease is resistant to dasatinib or
• They cannot tolerate dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate or
• The T315I gene mutation is present.